TY - JOUR
T1 - Fatigue in ANCA-associated vasculitis (AAV) and systemic sclerosis (SSc)
T2 - similarities with Myalgic encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A critical review of the literature
AU - van Eeden, Charmaine
AU - Osman, Mohammed S
AU - Cohen Tervaert, Jan Willem
N1 - Funding Information:
This manuscript was funded by the Dutch Kidney Foundation (17PhD01).
Funding Information:
J Cohen Tervaert and M Osman’s research is supported by unrestricted grants from the University of Alberta (Canada), Dutch Kidney Foundation, the University Hospital Foundation and Kaye Grants, Scleroderma Canada, and Boehringer Ingelheim. Additionally, M Osman is funded by the Arthritis Society (STAR career development award) and Scleroderma Canada. J Cohen Tervaert received speaker honoraria from Pfizer and Medexus. M Osman received speaker honoraria from Boehringer Ingelheim. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022/10/3
Y1 - 2022/10/3
N2 - INTRODUCTION: Persistent debilitating fatigue is a frequent complaint in patients with systemic autoimmune rheumatic diseases (SARDs). Fatigue is, however, frequently overlooked in the clinic, and patients who successfully achieve remission of their disease, often still have a lowered quality of life due to its persistence. How similar is this fatigue to Myalgic encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), what is this fatigue associated with, and what tools/approaches (if any), have resulted in the improvement of fatigue in these patients is poorly defined.AREAS COVERED: Similarities between the pathophysiology of ME/CFS, systemic sclerosis (SSc) and primary systemic vasculitides (PSV) are discussed, followed by an in-depth review of the prevalence and correlates of fatigue in these diseases. The authors reviewed literature from MEDLINE, APA PsycInfo, Embase, and CINAHL.EXPERT OPINION: Persistent fatigue is a prominent feature in SARDs and may not be associated with components commonly associated with disease activity and/or progression. Immune and metabolic commonalities exist between ME/CFS, SSc, and PSVs - suggesting that common pathways inherent to the diseases and fatigue may be present. We suggest that patients with features of ME/CFS need to be identified by treating physicians, as they may require alternative approaches to therapy to improve their quality of life.
AB - INTRODUCTION: Persistent debilitating fatigue is a frequent complaint in patients with systemic autoimmune rheumatic diseases (SARDs). Fatigue is, however, frequently overlooked in the clinic, and patients who successfully achieve remission of their disease, often still have a lowered quality of life due to its persistence. How similar is this fatigue to Myalgic encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), what is this fatigue associated with, and what tools/approaches (if any), have resulted in the improvement of fatigue in these patients is poorly defined.AREAS COVERED: Similarities between the pathophysiology of ME/CFS, systemic sclerosis (SSc) and primary systemic vasculitides (PSV) are discussed, followed by an in-depth review of the prevalence and correlates of fatigue in these diseases. The authors reviewed literature from MEDLINE, APA PsycInfo, Embase, and CINAHL.EXPERT OPINION: Persistent fatigue is a prominent feature in SARDs and may not be associated with components commonly associated with disease activity and/or progression. Immune and metabolic commonalities exist between ME/CFS, SSc, and PSVs - suggesting that common pathways inherent to the diseases and fatigue may be present. We suggest that patients with features of ME/CFS need to be identified by treating physicians, as they may require alternative approaches to therapy to improve their quality of life.
U2 - 10.1080/1744666x.2022.2116002
DO - 10.1080/1744666x.2022.2116002
M3 - (Systematic) Review article
C2 - 36045606
SN - 1744-666X
VL - 18
SP - 1049
EP - 1070
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
IS - 10
ER -